Aclaris Therapeutics vs Rani Therapeutics
ACRS and RANI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACRS and RANI compare
Aclaris Therapeutics is the larger company, worth 7.9 times as much as Rani Therapeutics ($577M against $73.4M).
Rani Therapeutics grew revenue faster over the last twelve months (449% versus −59.3% for Aclaris Therapeutics).
Rani Therapeutics keeps more of each dollar of sales as profit, with a net margin of −493% compared with −1244% at Aclaris Therapeutics.
Aclaris Therapeutics scores higher on the StockData Score (6 against 2 for Rani Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACRS | RANI |
|---|---|---|
| Size and price | ||
| Market cap | $577M | $73.4M |
| Share price | $3.92 | $0.526 |
| Change, 1 year | 62.7% | −75.2% |
| Change, 5 years | −71.6% | −98.5% |
| Beta (5Y) | 1.13 | 0.85 |
| Employees | 73 | 69 |
| StockData Score | ||
| Total score | 6 (better) | 2 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 90.1× | 11.1× (better) |
| P/B | 3.5× | 2.2× (better) |
| FCF yield | −13.1% (better) | −31.7% |
| Fair value | – | $0.366 |
| Margin of safety | – | −43.8% |
| Growth | ||
| Revenue growth (TTM) | −59.3% | 449% (better) |
| Revenue growth, 5Y average | 3.8% | 28.7% (better) |
| Profitability | ||
| Gross margin | 79.2% | – |
| Operating margin | −1414% | −530% (better) |
| Net margin | −1244% | −493% (better) |
| FCF margin | −1177% | −353% (better) |
| Return on equity | −55.5% (better) | −249% |
| Return on invested capital | – | −173% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −71.9× |
| Current ratio | 5.09 | 5.26 (better) |
| Altman Z-score | −0.44 (better) | −1.36 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 82.3% | 32.7% |
| Held by insiders | 13.3% | 30.6% |
| Insider net buying, 12 months | −$1.4M | $49.7K (better) |
| Short interest, % of float | 9.1% | 8.5% |
Go deeper
- ACRS stock overview
- ACRS income statement
- ACRS valuation and score
- RANI stock overview
- RANI income statement
- RANI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.